重酒石酸氢可酮(Hydrocodone bitartrate) - 药物靶点：Opioid receptors_在研适应症：疼痛_专利_临床

概要

基本信息

简介Hydrocodone bitartrate是一种阿片类止痛药，通常被称为“氢可酮”。其化学名为4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) 或morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5)。氢可酮是美国用于急性和慢性疼痛的最常用药物，2012年的处方量超过1.35亿。由于其易获取性和滥用模式，氢可酮被认为是引起滥用和误用的阿片类药物的主要驱动力。其机制是通过刺激阿片受体发挥镇痛作用。

药物类型

小分子化药

别名

酒石酸氢可酮、AFI-001、ATLP-03

+ [9]

靶点

Opioid receptors

作用方式

激动剂

作用机制

Opioid receptors激动剂(阿片样受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

疼痛

非在研适应症

慢性骨关节炎慢性疼痛终末期肾脏病+ [3]

原研机构-

在研机构

Purdue Pharma LP

非在研机构

Teva Branded Pharmaceutical Products R&D, Inc.

Societal CDMO Gainesville LLC

Zogenix, Inc.

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2013-10-25),

疼痛

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H29NO10

InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N

CAS号34195-34-1

关联

35

项与重酒石酸氢可酮相关的临床试验

NCT06780202

/ Recruiting临床2期IIT

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.
The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

开始日期2025-01-27

申办/合作机构

Emory University

NCT06585163

/ Not yet recruiting临床1期

A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers

This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.

开始日期2024-09-01

申办/合作机构

Quivive Pharma, Inc.

[+1]

NCT06232577

/ Active, not recruiting临床2期IIT

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

开始日期2024-03-27

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与重酒石酸氢可酮相关的临床结果

登录后查看更多信息

100 项与重酒石酸氢可酮相关的转化医学

登录后查看更多信息

100 项与重酒石酸氢可酮相关的专利（医药）

登录后查看更多信息

1,627

项与重酒石酸氢可酮相关的文献（医药）

2025-12-01·HISTOCHEMISTRY AND CELL BIOLOGY

Bioactive and degradable collagen-based hydrogel encapsulated with microspheres containing basic fibroblast growth factor (bFGF) and interleukin (IL)-10 promotes recovery following traumatic spinal cord injury in rats

Article

作者: Hjazi, Ahmed

Traumatic spinal cord injury (TSCI) is a severe event within the central nervous system, leading to the impairment of sensory and motor abilities at the injury site in the spinal cord. Current therapeutic approaches offer limited efficacy in improving recovery, underscoring the need to explore alternative treatments. In the present study, we examined the sustained co-delivery of basic fibroblast growth factor (bFGF) and interleukin-10 (IL-10), encapsulated in microspheres and incorporated into a collagen-based hydrogel, for its effects on the healing of TSCI in an animal model. Seventy-five male Sprague Dawley rats were randomly divided into five groups: control, TSCI, hydrogel, microspheres, and hydrogel loaded with microspheres (Hyd + Micro). Tissue samples were collected from the injury site for further evaluation. Compared to the TSCI group, treatment groups demonstrated notably higher numerical densities of neurons and greater motor neuron health, as well as increased levels of vascular endothelial growth factor (VEGF) and antioxidative factors (catalase [CAT], glutathione [GSH], and superoxide dismutase [SOD]), and improved neurological function scores (electromyography [EMG], Basso-Beattie-Bresnahan (BBB) test, and narrow beam-walking test [NBT]). These changes were most pronounced in the Hyd + Micro group. The treatment also led to a significant decrease in the counts of apoptotic and glial cells, alongside reduced levels of malondialdehyde (MDA) and pro-inflammatory cytokines (IL-1β and TNF-α), with the most notable enhancements seen in the Hyd + Micro group. These findings indicate that the co-delivery of bFGF and IL-10 encapsulated in microspheres within a collagen-based hydrogel provides enhanced neuroprotective effects in TSCI animal models.

2025-09-01·ACTA ANAESTHESIOLOGICA SCANDINAVICA

The Association of Preoperative Hydrocodone and Acetaminophen With Total Opioid Requirement, and Pain Experience in Children Undergoing Adenotonsillectomy

Article

作者: Nguyen, Duc T. ; Adler, Adam C. ; Aras, Sukru ; Kim, Hye Min ; Vernick, Robert C. ; Messner, Anna H. ; Tanwani, Anika

ABSTRACT:

Background:

Pre‐emptive analgesia may be of benefit in reducing total opioid use and improving the pain experience perioperatively. However, there is conflicting evidence as to the benefits of pre‐emptive analgesia, with limited evidence in children. The aim of this study was to examine the association between preoperative use of hydrocodone with acetaminophen and total opioid consumption in children undergoing adenotonsillectomy.

Methods:

This was a retrospective cohort study of the children undergoing adenotonsillectomy surgery at Texas Children's Hospital between 11/2017 and 12/2018. Preoperative use of hydrocodone with acetaminophen was the exposure of interest. The primary outcome was total perioperative opioid consumption calculated as oral morphine equivalents (OME). Secondary outcomes of interest included: post‐anesthesia care unit (PACU) pain experience and time to discharge. We used multivariable linear regression to estimate the association of hydrocodone with acetaminophen on the outcomes.

Results:

A total of 1082 patients met inclusion criteria, 366 (33.8%) received pre‐operative hydrocodone with acetaminophen. There was no difference in the total intraoperative and postoperative OME between groups, mean OME of 0.49 mg/kg (±0.23) in the HA group versus 0.50 mg/kg (±0.27) in the control group; p = 0.56. For PACU discharge, the median [IQR] for PACU discharge time was longer in the patients who did not receive preoperative HA, at 39.0 [25.0–58.0] versus 30.0 [20.0–46.0] min for the preoperative HA group. Use of preoperative HA was associated with a 61% likelihood of having a PACU discharge time exceeding 30 min, with an odds ratio (OR) of 0.39 (95% CI, 0.28, 0.54; p < 0.001). Use of preoperative HA resulted in a greater likelihood of exhibiting a maximal pain score of 0–3 in PACU, with an OR of 2.16 (95% CI, 1.56–2.99; p < 0.001), as well as an increased likelihood of a having a maximum recorded pain score of zero, with an OR of 1.85 (95% CI, 1.34–2.56; p < 0.001).

Conclusions:

Pre‐operative hydrocodone with acetaminophen was associated with improved outcomes with respect to PACU pain experience and time to discharge. The total OME increase was limited to the pre‐operative HA dose.

2025-09-01·Oral Surgery Oral Medicine Oral Pathology Oral Radiology

A new prescribing strategy combined with multimodal analgesics reduces unused opioid doses: a prospective observational study

Article

作者: Kendell, Barry ; Meier, Caroline ; Hannan, Elisa ; Phillips, Ceib ; White, Raymond ; Reside, Glenn ; Keefe, Susan

OBJECTIVE:

Following surgery, the primary challenge is to effectively manage acute pain while minimizing opioid usage. An established protocol in managing postoperative pain in third molar surgery has not been well described.

STUDY DESIGN:

This prospective observational study included patients with at least 2 mandibular third molars removed in the University of North Carolina Oral Maxillofacial Surgery Clinic. Patients were treated with a multimodal analgesic regimen emphasizing medications with anti-inflammatory, long-acting, and short-acting properties, along with 2 separate prescriptions of 4 doses of Hydrocodone/acetaminophen (APAP). Daily post-surgery pain scores, medication use, and opioid prescription filled history were analyzed.

RESULTS:

Data were analyzed from 96 patients. The combination of anti-inflammatory medications administered intra- and postoperatively, long-acting local anesthesia, and a limited number of prescribed opioids resulted in recovery to "little-to-no" pain for the average pain scores by day 4 and worst pain scores by day 6. Additionally, 52 patients (54%) did not fill an opioid prescription. Twenty-seven patients (28%) filled 1 prescription and 17 patients (18%) filled 2 prescriptions. On average, a 1.3 opioid dose was used post-operatively, ranging from 0 to 8 doses.

CONCLUSIONS:

By combining medications with anti-inflammatory properties, long-acting local anesthesia, and a unique prescribing practice, we were able to achieve satisfactory pain control and limit leftover opiate use. (Oral Surg Oral Med Oral Pathol Oral Radiol YEAR;VOL:page range).

65

项与重酒石酸氢可酮相关的新闻（医药）

2025-08-28

·PRNewswire

Imbed Biosciences Launches Dual-Action Wound Matrix Integrating Bioburden Management and Pain Relief in a Single Solution

MIDDLETON, Wis., Aug. 28, 2025 /PRNewswire/ -- Imbed Biosciences Inc., a leader in advanced wound care technology, today announced the launch of SAM™ PainGuard™ with Lidocaine, a groundbreaking addition to its acute care portfolio of fully synthetic, antimicrobial, and biocompatible wound matrices. This innovation introduces two new product brands: Surgaflex™ PainGuard™, designed for surgical wounds, and Pelashield™ PainGuard™, tailored for burn and trauma wound management. This launch highlights the versatility of Imbed's SAM™ Antimicrobial Technology platform, which uniquely integrates multiple wound care agents into a single matrix composed of bioresorbable polymers. The result is a dual-action solution that delivers both antimicrobial protection and acute pain relief—streamlining wound care and improving patient outcomes. "Nearly 90% of patients report moderate to severe pain following surgery," said Terry Bromley, CEO of Imbed Biosciences. "Managing this pain effectively from the start is critical—not only to reduce reliance on systemic pain medications, including opioids, but also to prevent long-term complications such as anxiety, PTSD, and delayed healing, which can be a challenge especially in burn care." "These clinical challenges were the driving force behind the development of SAM™ PainGuard™," added Gaurav Pranami, Ph.D., Vice President, Research & Development at Imbed. "By incorporating lidocaine alongside antimicrobial silver, we've created a matrix that addresses both bioburden and pain in a convenient, unit-dose format." The PainGuard™ matrix delivers a controlled release of lidocaine HCl comparable to a 4% ointment, with over 80% released within the first 30 minutes to provide immediate pain relief. It is indicated for a wide range of wound types—including surgical, burn, donor site, trauma, and chronic wounds—and is especially beneficial following painful excisions and also procedures such as dressing changes and debridement. Pre-launch product evaluations have resulted in strong endorsements from participating physicians, with testimonials such as the following praising its ability to effectively manage patient pain and offer a convenient solution for clinicians. "This patient stopped taking her hydrocodone on day one, and rates her pain 1/10 since the procedure. This doesn't happen with this type of bunion surgery!" Damian Dauphinee, DPM, Podiatry "The matrix is easy to use, easy to place, and my patient is pain free." Dr. Aaron Cernero, DO, General Surgery Product Highlights Dual-action, ultra-thin matrix combines antimicrobial silver and lidocaine HCl Porous, bioresorbable polymer conforms to wound micro-textures and does not require removal Synthetic composition eliminates product-related infection risks associated with animal-derived products Low, non-toxic levels of ionic and metallic silver provide 72 hours of sustained, 99.99% microbial reduction Acute pain relief for up to 3 hours FDA 510(k)-cleared (K211943) Ready-to-use, unit-dose format for consistent and safe application "We have successfully engineered and translated our unique multi-agent matrix into a clinically-relevant solution that enables uniform coverage and controlled dosing," explains Sanjay Gupta, Vice President, Supply Chain, "with a design that simplifies clinical workflows and reduces possible side-effects by preventing uneven lidocaine applications, which can occur with gels or ointments." Surgaflex™ PainGuard™ and Pelashield™ PainGuard™ are now available in the U.S. and join Imbed's expanding portfolio of SAM™-based wound care solutions, which includes Microlyte®, Surgaflex™, and Pelashield™, indicated for chronic, acute, and burn wounds respectively. About Imbed Biosciences Inc. Imbed Biosciences is a privately held medical device company pioneering the next generation of wound care with SAM™ Antimicrobial Technology. SAM™ acts as a platform, designed to integrate multiple therapeutic agents into ultra-thin, biocompatible matrices to support skin regeneration and healing while managing bioburden, across a wide range of acute and chronic wounds. For more information, visit ImbedBio.com and connect with us on LinkedIn, Instagram, and Facebook. Media Contact: Hillary Rush Vice President of Marketing Imbed Biosciences Inc. 📧 [email protected] 🌐 SOURCE Imbed Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-08-05

·新药猎人笔记

Vertex盘前大跌：Nav1.8抑制剂遭双杀

2025年8月5日，Vertex Pharmaceuticals公司宣布，其在研的非阿片类止痛药VX-993在治疗拇囊炎切除术后急性疼痛的二期临床试验中未能达到主要终点。受此消息影响，Vertex公司股价盘前大跌13%！该试验是一项双盲、安慰剂对照研究，共招募了367名接受拇囊炎切除手术的患者。试验测试了三种口服剂量的VX-993（180/90毫克、70/35毫克和10/5毫克），并评估了它们与安慰剂相比减轻术后急性疼痛的能力。试验结果在一项涉及 367 人的研究中，术后48小时内，该药物的三种剂量均未显著优于安慰剂。尽管较高剂量在数值上表现较好，但其效果仍逊于服用常见止痛药氢可酮/对乙酰氨基酚（商品名：维柯丁）的患者组。最常见的不良事件包括恶心、头晕、头痛和呕吐。这表明VX-993在安全性方面表现良好，但其疗效仍需进一步优化。基于这些结果，公司不再将VX-993作为急性疼痛的单一疗法进行研究。该公司还在进行VX-993用于糖尿病周围神经病变（一种慢性疼痛）的二期临床试验，计划招募约300名患者。图源：https://www.biopharmadive.com/news/vertex-pain-non-opioid-drug-fda-approval-journavx/738721/ 此外，不再计划对已获批的Nav1.8抑制剂 Journavx 进行治疗坐骨神经痛的三期临床试验。这一决定是在美国食品药品监督管理局告知该公司“他们看不到”获得外周神经性疼痛（包括糖尿病周围神经病变等慢性疼痛）广泛适应症的途径之后做出的。结束语： VX-993是Vertex公司开发的下一代Nav1.8钠通道抑制剂，旨在通过选择性抑制Nav1.8通道来阻断外周神经系统中的疼痛信号传递。此前，Vertex的另一款Nav1.8抑制剂VX-548已获得美国FDA批准用于治疗中度至重度急性疼痛，并显示出良好的疗效和安全性。一日两款Nav1.8抑制剂遭双杀，Vertex想要突破更多的疼痛适应症还有漫长的路要走。

临床2期临床3期

2025-08-05

·药时代

打不过安慰剂？如何冲击千亿美元市场

全文共2000字，共1图预计阅读时间：5分钟在非阿片类镇痛药的研发中，Vertex遭遇了新的挫折。其Nav1.8钠通道抑制剂VX-993在一项2期临床试验中未能在疼痛缓解方面优于安慰剂效果。该结果于8月4日美股收盘后公布。与此同时，Vertex透露，美国FDA将拒绝批准Journavx（VX-548）用于更广泛的适应症。这一系列不利消息，让刚公布第二季总收入29.6亿美元，同比增长12%的Vertex根本笑不起来。逊于安慰剂这项双盲、安慰剂对照研究共纳入367名接受拇囊炎（拇外翻）手术的患者。试验测试了VX-993的三种口服剂量，并评估其在术后急性疼痛中的镇痛效果。研究的主要终点指标为SPID48（0至48小时疼痛强度差值的时间加权总和），该指标综合反映疼痛缓解的程度与持续时间。SPID48值越高，表明48小时内累积的镇痛效果越好。来源：Vertex官方披露虽然猛一看， VX-993各剂量试验组的SPID48数值均略高于安慰剂组，但P值远大于医学研究中设定的0.05，这就有理由怀疑这个差异是因为运气，而非药物的真实效果。此外，三个剂量组的置信区间均包含0（即无差异）甚至负值（表示可能劣于安慰剂），进一步表明其疗效缺乏统计学支持。值得注意的是，作为阳性对照的活性药物组（氢可酮/对乙酰氨基酚）表现出显著优于安慰剂的镇痛效果（SPID48差异为44.2，95% CI: 14.0–74.4，p=0.0043 < 0.05）。这一阳性结果具有重要意义，它验证了：研究设计的科学性，具备检测有效镇痛作用的能力；患者人群的代表性，对已知有效药物有预期反应；疼痛评估方法的敏感性，能够准确捕捉疼痛变化；安慰剂效应是在预期范围内的。这些试验数据再次强有力地支持了结论：VX-993在三种剂量下，均未在术后48小时内显著缓解疼痛，其效果甚至可能略逊于安慰剂。这并非源于试验设计或执行缺陷，而是该药物本身疗效不足。欣慰的是，VX-993的安全性数据与安慰剂相似，最常见的不良反应包括恶心、头晕、头痛和呕吐。珠玉在前，为何还推出VX-993 作为NaV1.8领域的领头羊，Vertex先后折戟VX-128，VX-961，VX-150等多个分子，或因剂量安全性问题，或因PK特征不符合开发要求。重磅止痛药Journavx成功地提高了NaV1.8抑制活性和选择性，但似乎在糖尿病周围神经痛（DPNP）和疼痛性腰骶神经根病（LSR）上的疗效依然比较有限。在2期的临床中发现，Journavx Day1的平均Tmax为6h,但活性代谢产物血药浓度达峰时间(Tmax)间为12h。对于急性疼痛，如果可以进一步缩短达到Tmax 的时间，尤其是活性药物Tmax 的进一步缩短，可以显著提高药物起效时间。这或许也是Vertex快速推进VX-993临床开发的原因，希望通过结构优化，在药效和药代动力学（PK）等方面实现进一步提升，以开发出安全性、有效性优于Journavx的新一代非阿片类镇痛疗法。然而，“升级版”第三代的VX-993还是未能超越Journavx的出色疗效【3期临床数据显示，在接受拇囊炎切除手术的患者中，Journavx疗法的SPID48平均差异为29.3（95% CI：14.0，44.6；P=0.0002）】，甚至在关键研究中未能显示出优于安慰剂的效果，铩羽而归。 FDA拒批“魔掌”伸向Vertex 不过，Journavx近日也摊上事了。Vertex公司透露，美国FDA目前不愿批准其用于广泛治疗周围神经性疼痛。今年1月底，Journavx已获FDA批准上市，成为近25年来首个获批的新型止痛药，也是自20世纪80年代以来首款非阿片类急性疼痛治疗药物。这一突破曾被寄予厚望，有望为美国止痛药市场带来颠覆性变革，助力缓解日益严峻的阿片类药物滥用危机。然而，美中不足的是，该药目前仅被批准用于治疗中至重度急性疼痛，其适用范围仍较为有限，大量慢性疼痛等临床需求尚未覆盖。此次FDA拒绝扩展其适应症，尽管令人遗憾，但在当前FDA高层人事变动的背景下，对监管审批呈审慎态度也不意外。药时代近期在《多款药物惨遭FDA拒批！居然因为... 》中报道过：细胞疗法Deramiocel和溶瘤病毒疗法RP1等多个项目均因人事变动收到了CRL。鸦片危机催生千亿金矿 VX-993的临床开发失败，叠加Journavx扩展适应症被拒，令资本市场对Vertex公司的前景产生复杂情绪。然而，业内人士普遍认为，此次风波的“余震”不会持续太久，对Journavx等Nav1.8钠通道抑制剂的整体市场潜力仍持乐观态度。无上瘾性的止痛药是美国急需的，而这恰恰是Journavx最大的卖点。 Journavx精准靶向Nav1.8钠通道，这一通道特异性表达于外周疼痛感知神经元中。这一机制优势意味着药物可有效阻断疼痛信号的传递，而不会干扰心脏或中枢神经系统功能。由于作用机制是阻断这条外周通路，因此不会像阿片类药物那样激活大脑奖赏系统、引发欣快感或成瘾风险，从根本上规避了滥用隐患。这一特性在当前美国深陷“阿片危机”的背景下显得尤为可贵。自1999年以来，美国已有超过19万人死于奥施康定等阿片类止痛药物的滥用。根据美国缉毒局（DEA）数据，2023年全美因药物过量致死人数超过10.7万，其中近70%由芬太尼及其他阿片类物质引发。美国国会联合经济委员会2022年发布的报告指出，阿片类药物滥用已给美国经济造成近1.5万亿美元的损失，约占当年GDP的7%。严峻的公共卫生危机催生了一个巨大的“蓝海”市场。据Mordor Intelligence数据显示，2021年全球疼痛管理市场规模达794亿美元，预计到2027年将攀升至1207亿美元，年复合增长率达7.39%。在GLP-1类减肥药热潮之后，镇痛药被视为下一个有望突破千亿级美元的医药“金矿”。若Vertex能凭借Journavx率先确立在无成瘾性止痛药领域的领导地位，其市场前景不可估量。但其它管线若想和Journavx打擂台，还是先打过安慰剂吧！，参考资料： 1.https://www.fiercebiotech.com/biotech/vertex-drops-journavx-follower-acute-pain-after-complete-phase-2-failure 2.安慰剂疗效显著？Vertex一夜蒸发130亿美元（药时代） 3.止痛药 “觉醒时代” 开启（药时代）4.https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-vx-993-treatment-acute 5.Na1.8- VX-548依然有巨大改进的空间（Healthcare Weekly) 6.值Vertex一季报之际，一窥其疼痛管理管线(MNC观察) 7.营收逆势增长12%，却被FDA和管线双重泼冷水，Vertex遭遇“甜苦交加”一日(思索新知) 8.其他公开资料图片来源：即梦AI 2025-08-05 Q2亏损8亿美元、裁员10%、CEO拒绝并购交易 2025-08-04 患者死亡！通用型CAR-T先驱遇挫 2025-08-04 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击这里，查看更多精彩！

100 项与重酒石酸氢可酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重酒石酸氢可酮	R05DA03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	美国	Societal CDMO Gainesville LLC	2013-10-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2010-11-01
慢性疼痛	临床3期	美国	Zogenix, Inc.	2010-05-01
腰痛	临床3期	美国	Zogenix, Inc.	2010-03-01
慢性骨关节炎	临床2期	-	Zogenix, Inc.	2002-09-01
术后疼痛	临床2期	-	Zogenix, Inc.	2002-08-01
终末期肾脏病	临床1期	美国	Cephalon, Inc.	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01402375 (CTgov)	临床3期	镇痛 \| 急性疼痛	720	Hydrocodone (first trial) (Hydrocodone (First Trial))	夢餘選憲廠憲餘鬱夢鏇(淵窪鏇醖觸遞積膚衊醖) = 蓋膚膚積願餘選廠遞衊憲鹽鬱構艱襯壓壓遞築 (襯鹹鑰鬱齋網壓鑰網獵, 1.7) 更多	-	2018-05-01
				Codeine (Codeine (First Trial))	夢餘選憲廠憲餘鬱夢鏇(淵窪鏇醖觸遞積膚衊醖) = 膚齋願網鏇襯襯憲顧蓋憲鹽鬱構艱襯壓壓遞築 (襯鹹鑰鬱齋網壓鑰網獵, 1.8) 更多
NCT01240863 (CTgov)	临床3期	腰痛 \| 骨关节炎 \| 慢性疼痛	391	Placebo (Placebo (Double-blind Treatment Period))	獵齋製簾淵鏇壓膚蓋鏇(糧襯廠遞鹹觸簾選膚構) = 鹽範齋製淵願鑰窪廠網窪衊糧網鹽憲餘顧選願 (淵淵壓醖積淵鑰繭憲夢, 0.169) 更多	-	2017-06-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	獵齋製簾淵鏇壓膚蓋鏇(糧襯廠遞鹹觸簾選膚構) = 糧醖願鹹襯遞簾鹹遞鹽窪衊糧網鹽憲餘顧選願 (淵淵壓醖積淵鑰繭憲夢, 0.176) 更多
NCT01922739 (CTgov)	临床3期	腰痛	182	Placebo+Hydrocodone ER	觸鏇鬱範範積鏇艱壓願 = 壓觸壓範蓋壓鏇選構餘鬱壓鹹顧鏇願簾齋壓顧 (顧夢鹹範鹽艱夢淵鹹範, 積選繭糧選夢餘製餘鑰 ~ 選鏇夢衊築壓網獵鬱壓) 更多	-	2017-06-02
NCT01789970 (CTgov)	临床3期	腰痛	625	Placebo (Placebo (Double-blind Treatment Period))	鑰膚糧蓋製膚鬱鹽夢積(壓構遞鏇築築顧醖網觸) = 艱鏇鬱鬱衊窪鑰鹽餘壓窪醖壓糧憲餘餘選鬱糧 (壓蓋淵鹽憲蓋範鹹鹽鏇, 0.145) 更多	-	2017-04-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	鑰膚糧蓋製膚鬱鹽夢積(壓構遞鏇築築顧醖網觸) = 鹹選鏇製壓窪憲夢壓淵窪醖壓糧憲餘餘選鬱糧 (壓蓋淵鹽憲蓋範鹹鹽鏇, 0.134) 更多
NCT01517295 (CTgov)	临床4期	慢性疼痛	30	Hydrocodone (Group 1)	製遞淵簾積獵夢窪窪淵(觸簾壓膚鹽構蓋膚顧積) = 廠鹹築壓襯蓋簾鹹醖顧築網膚觸願鏇製鹹蓋鏇 (膚築願範衊艱襯餘鹹製, 0) 更多	-	2016-07-28
				Hydrocodone (Group 2)	製遞淵簾積獵夢窪窪淵(觸簾壓膚鹽構蓋膚顧積) = 憲顧構衊鹽積鬱膚鏇築築網膚觸願鏇製鹹蓋鏇 (膚築願範衊艱襯餘鹹製, 0) 更多
NCT01859715 (CTgov)	N/A	药物相互作用	502	Oxycodone (Oxycodone Group)	醖製鹹衊繭觸鏇簾廠觸(膚憲夢網選顧構廠獵餘) = 獵艱遞顧鑰憲鹽夢願鏇廠醖鹽築淵憲獵顧積網 (製壓淵餘繭淵選壓願簾, 糧繭顧範觸選餘糧積壓 ~ 窪鬱構壓遞糧製獵襯築) 更多	-	2016-05-05
				Hydrocodone (Hydrocodone/Acetaminophen Group)	醖製鹹衊繭觸鏇簾廠觸(膚憲夢網選顧構廠獵餘) = 餘憲窪廠願製遞遞選網廠醖鹽築淵憲獵顧積網 (製壓淵餘繭淵選壓願簾, 鏇蓋觸積壓築蓋獵窪憲 ~ 壓製繭襯壓鑰構憲鏇範) 更多
NCT01400139 (CTgov)	临床3期	慢性疼痛	922	Hydrocodone bitartrate (HYD) (HYD Core Study)	構廠遞繭築齋鬱壓構製 = 構構鏇壓積蓋窪遞獵醖鏇網製壓願醖鑰蓋製蓋 (範簾築壓齋衊範獵壓廠, 選淵衊觸積鬱鏇糧蓋蓋 ~ 醖選淵襯夢繭積鬱夢鹹) 更多	-	2014-12-04
				Hydrocodone bitartrate (HYD) (HYD Extension Period)	構廠遞繭築齋鬱壓構製 = 積鏇醖獵膚窪範築構願鏇網製壓願醖鑰蓋製蓋 (範簾築壓齋衊範獵壓廠, 艱齋遞鹽蓋願製鏇鑰夢 ~ 窪廠鑰糧淵網衊衊壓簾) 更多
NCT01452529 (CTgov)	临床3期	腰痛	905	Hydrocodone bitartrate (Hydrocodone Bitartrate)	蓋遞夢艱觸觸憲艱觸願(製鏇衊繭觸淵顧壓襯壓) = 顧衊憲鏇艱齋遞糧構遞築憲齋衊憲積獵廠醖鏇 (選襯壓醖醖壓遞鏇獵願, 0.13) 更多	-	2014-12-04
				Placebo to match hydrocodone bitartrate q24h tablets (Placebo)	蓋遞夢艱觸觸憲艱觸願(製鏇衊繭觸淵顧壓襯壓) = 糧淵膚壓選襯網齋鏇願築憲齋衊憲積獵廠醖鏇 (選襯壓醖醖壓遞鏇獵願, 0.13) 更多
NCT01115569 (CTgov)	临床3期	慢性疼痛	424	Hydrocodone Bitartrate (Open-label Hydrocodone Bitartrate Extended Release Capsules)	鹽製衊齋餘築繭夢壓衊(艱鏇鏇遞積醖醖製網簾) = 憲夢簾糧鬱憲鬱顧襯範顧齋鬱鏇廠壓獵繭製憲 (鏇蓋鏇鹽簾糧齋選獵鑰, 2.2)	-	2014-04-25
				Hydrocodone Bitartrate (Conversion/Titration Phase)	膚願鹹築齋願窪顧觸窪(糧襯積壓蓋糧遞齋壓齋) = 鏇膚簾憲構願範艱繭鹽淵壓襯觸積範餘餘構淵 (顧製遞糧製獵築齋壓餘, 鏇願簾鑰積鏇夢鏇壓繭 ~ 艱願遞鹽鏇遞顧獵積鏇) 更多
NCT01081912 (CTgov)	临床3期	腰痛	510	Hydrocodone bitartrate (Hydrocodone Bitartrate Capsules)	膚鹹襯糧鹽糧製餘膚遞(鹽糧夢繭鹹壓淵鏇範夢) = 鹽艱鏇衊繭願鏇製顧積顧醖壓繭鬱衊鬱構積鬱 (鑰鹹築艱繭齋醖壓艱夢, 1.563)	-	2014-04-21
				Placebo (Placebo Comparator)	膚鹹襯糧鹽糧製餘膚遞(鹽糧夢繭鹹壓淵鏇範夢) = 獵蓋壓襯窪壓範膚夢窪顧醖壓繭鬱衊鬱構積鬱 (鑰鹹築艱繭齋醖壓艱夢, 1.550)